Latest news
Iconovo adds business development experience with new CEO
So far, 2020 has brought several advancements for the Swedish dry powder inhaler company Iconovo. A major stepping stone was the change of CEO in April.…
Iconovo signs regional licensing agreement for ICOcap® formulations with BNC Korea
Iconovo announce that the company has signed a know-how license agreement granting BNC Korea Co Ltd the exclusive rights to use the know-how to manufacture…
Press releases
May 07, 2025, 14:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
May 06, 2025, 18:20
News
IR
English
Correction
Regulatory
Listing Regulation
Report
Annual
May 06, 2025, 13:40
News
IR
English
Regulatory
Listing Regulation
Report
Annual
Apr 25, 2025, 08:15
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 24, 2025, 15:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Apr 24, 2025, 15:00
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Apr 24, 2025, 08:55
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 24, 2025, 08:37
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:37
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:35
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 24, 2025, 08:35
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
English
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
Swedish
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
English
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
Swedish
Corporate Action
Other
Feb 27, 2025, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 27, 2025, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Jan 13, 2025, 08:30
News
IR
English
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
